Clinical Trial Update: Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours [NA]

View source ↗

Summary

GT307, an autologous tumor-infiltrating lymphocyte therapy from Grit Biotechnology, is currently recruiting for treatment of patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GT307 (Autologous tumor-infiltrating lymphocytes (GT307))

Snippet

Sponsor: Grit Biotechnology | Conditions: Adult | NA | Status: RECRUITING